BBOT trades 356.7% below Wall Street's consensus target of $19.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BBOT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, BridgeBio Oncology Therapeutics Inc. (BBOT) has a Wall Street consensus price target of $19.00, based on estimates from 8 covering analysts. With the stock currently trading at $4.16, this represents a potential upside of +356.7%. The company has a market capitalization of $333M.
Analyst price targets range from a low of $15.00 to a high of $22.00, representing a 37% spread in expectations. The median target of $20.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BBOT trades at a trailing P/E of -1.0x. Analysts expect EPS to grow +99.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BBIOBridgeBio Pharma, Inc. | $12.9B | $65.71 | $110.09 | +67.5% | Buy | — | 27 |
 KYMRKymera Therapeutics, Inc. | $9.5B | $115.47 | $136.75 | +18.4% | Buy | — | 27 |
 TPVGTriplePoint Venture Growth BDC Corp. | $200M | $4.92 | $5.00 | +1.6% | Hold | 5.5x | 12 |
 RVMDRevolution Medicines, Inc. | $40.6B | $190.74 | $247.00 | +29.5% | Buy | — | 24 |
 KRYSKrystal Biotech, Inc. | $10.1B | $341.75 | $383.75 | +12.3% | Buy | 44.7x | 17 |
 AUPHAurinia Pharmaceuticals Inc. | $2.1B | $16.40 | $16.00 | -2.4% | Buy | 17.4x | 15 |
 MGNXMacroGenics, Inc. | $242M | $3.80 | $6.00 | +57.9% | Buy | — | 22 |
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.3B | $26.38 | $38.00 | +44.0% | Buy | 53.1x | 12 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
Quick answers to the most common questions about buying BBOT stock.
The consensus Wall Street price target for BBOT is $19, representing 356.7% upside from the current price of $4.16. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BBOT has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies 356.7% upside from current levels.
BBOT's current price is $4.16 with a consensus target of $19 (356.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $22 for BBOT, while the most conservative target is $15. The consensus of $19 represents the median expectation. These targets typically reflect 12-month expectations.
BBOT is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BBOT stock forecast based on 8 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $15 (bear case) to $22 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BBOT, with a "Buy" consensus rating and $19 price target (356.7% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BBOT analyst price targets range from $15 to $22, a 37% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.